



Your Vaccines CDMO Partner for Life

Advancing vaccines from pre-clinical to commercial supply across multiple modalities including mammalian, microbial and insect cell culture for viral/bacterial and non-viral vaccines.

Comprehensive End-to-End Service





Partners for Life

<u>Contact us</u> to get the latest updates on our network and capabilities.

Global Vaccine Capabilities












Sites and Locations	College Station Texas, USA	RTP North Carolina, USA	Billingham, UK	Holly Springs North Carolina, USA	Hillerød, DK
Overview	High-Throughput Protein and Viral Vector Vaccine Development and Drug Substance, Drug Product Manufacture (Clinical and Commercial)	Recombinant Protein Vaccine Development and Drug Substance Manufacture (Clinical and Commercial)		Large-Scale Vaccine Manufacture Capabilities and High-Throughput Filling and Finished Goods (Clinical and Commercial)	
Technology and Platforms	CHO, Insect Cell (Sf9, Sf+), HEK293, MDCK, A549, HeLa	CHO, Insect Cell (Sf21, Sf9, BIIC), NSO, E. coli, S. cerevisiae, P. pastoris		CHO, Insect Cell-capable	
Experience	Sub-unit vaccines Live / Attenuated viral vectors Split-antigen (i.e. influenza)	Mammalian, Insect, and Microbial-derived sub-unit vaccines Virus-Like Particle-based Vaccines		Sites are primarily focused on monoclonal antibody based programs, but are capable of producing high-throughput vaccines at very large quantities.	
Capacity	Two suites each with 4 x 2,000 L Single-Use Future Expansion: Two suites each with 2 x 5,000 L Single-Use	Mammalian/Insect up to 2,000 L Microbial up to 2,000 L	Mammalian/Insect up to 2,000 L Microbial up to 5,000 L	Three suites each with 4 x 20,000 L Stainless Production (5 suites by end 2026) Total capacity: 12 x 20,000 L	Four suites each with 4 x 20,000 L Stainles: Production (4 suites by end 2027 Total capacity: 12 x 20,000 L
Throughput	Base Case: ~50 - 100 x 2,000 L DS Batches per year / suite Future expansion: 100+ x 5,000 L DS batches per year/suite	Base Case: ~20 batches per year in each asset	Base Case: ~20 batches per year in each asset Future Expansion: 100+ 2,000 - 5,000 L DS batches per year	Drug Substance: 50 – 85 x 20,000 L batches per year / suite Drug Product: 30M units per year	Drug Substance: 50 – 85 x 20,000 L batches per year / suite Drug Product: 30M units per year

Vaccine Drug Product and Finished Goods Services

Development and manufacturing capabilities designed with patient safety and centricity in mind.

For your liquid drug product we offer clinical batches up to 10,000 units in RTU nested vial format. For late phase clinical and commercial batches we offer up to 150,000 units using RTU nested components in vial, syringe, or cartridge format.

- Drug product process and formulation development, and process characterization support
- Accelerated and long-term stability studies
- Release of clinical and commercial products including European qualified persons
- Assembly, labeling and packaging support under our finished goods services:
 - o Assembly into auto-injectors and PFS components
 - o Labeling of vials, PFS and auto-injectors
 - o Primary packaging in single or multi-unit pack format
 - o Secondary packaging





Contact us to discuss your science.

USA

College Station, Texas 3939 Fujifilm Way College Station, TX 77845 +1 979 431 3500

DENMARK

Hillerød Biotek Allé 1 3400 Hillerød +45 7741 6000

HEA

Holly Springs, North Carolina 100 Biotechnology Avenue Holly Springs, NC 27540 (Coming online 2025)

UNITED KINGDOM

TeessideBelasis Avenue
Billingham, TS23 1LH
+44 1642 363511

JSA

Research Triangle Park, North Carolina 101 J Morris Commons Lane Morrisville, NC 27560 +1 919 337 4400

JAPAN

R7 Building, 7-12-2 Roppongi Minato-ku, Tokyo 106-0032 +81 3 6871 7736

JSA

Thousand Oaks, California 2430 Conejo Spectrum Street Thousand Oaks, CA 91320 +1 805 699 5579



fujifilmdiosynth.com

Email: contactfdb@fujifilm.com



